The cellular immune response to cancer is complex and involves a diverse repertoire of immunoregulatory interactions principally involving antigen presenting.

Slides:

Advertisements

Similar presentations

Advanced Cancer Topics Journal Review 4/16/2009 AD.

Advertisements

Overview of Targeted Therapy Mechanisms November 11, 2011 Targeted Therapies and Biological Therapies SIG.

Schema for a human microbiome study

Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against Eph family receptors Sara Charmsaz, Andrew M. Scott,

Figure 1 CTLA-4 and PD-1–PD-L1 immune checkpoints

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Immunomodulatory monoclonal antibodies and armoured chimeric antigen receptor (CAR) T cells overcome immune suppression Figure 1 | Immunomodulatory.

Advances in Specific Immunotherapy for Prostate Cancer

Figure 7 Clinical options for HCC therapy

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Engineering regulatory T cells against factor VIII inhibitors

Nat. Rev. Clin. Oncol. doi: /nrclinonc

The PI3K/Akt signalling and its activation in cancer

Nat. Rev. Clin. Oncol. doi: /nrclinonc

The hallmarks of adenovirus infection

Schematic diagram of antibody drug conjugate

Latest Advances in Chemotherapeutic, Targeted, and Immune Approaches in the Treatment of Metastatic Melanoma Darshil J. Shah, MD, MPH, Roxana S. Dronca,

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Antigen-induced regulatory T cells

Figure 1 A schematic representation of the HER2 signalling pathway

Figure 2 Co-stimulatory receptors as immunomodulatory targets

Figure 4 Combination immunotherapeutic approaches with imatinib

The core pillars and thematic hallmarks of anti-tumour immunity governing response to immune checkpoint blockade Figure 2 from Cogdill et al. British.

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

(A) An overview of the JAK/STAT signalling pathway.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Drug cycling with collateral sensitivity

Molecular approaches to HER2 targeted therapy

An overview of oncogenic KRAS-driven RAF/MEK/ERK and PI3K/PDK1/AKT signalling networks in pancreatic cancer Figure 1 from Eser et al. British Journal.

Model of the function of TBX2 in RMS.

Figure 2 from Sancho et al.

The cancer stem cell concept in cancer progression and metastasis

The putative genomic evolution of prostate cancer from normal epithelium to castrate-resistant, metastatic cancer Figure 2 from Mitchell and Neal British.

Figure 1 from B Zhu British Journal of Cancer (2015) 112, ; doi: /bjc

Sequencing of targeted therapies in HER2-positive metastatic breast cancer Figure 2 from Singh et al. British Journal of Cancer (2014) 111,

Microglia and the Immune Pathology of Alzheimer Disease

A. Craig Lockhart, Mace L. Rothenberg, Jordan D. Berlin

A hypothetical scheme targeting autophagy for glioblastoma sensitisation during radio-chemotherapy with TMZ Figure 1 from Michael I Achilleas G and.

Figure 1 The role of CTLA4 and PD1 in T cell activation

Targets for immunotherapy of liver cancer

Figure 2 Approaches to improve CAR-T-cell therapy

Figure 2 Site of action of checkpoint inhibitors and agonists being

Robert J Korst, MD, Ronald G Crystal, MD

Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against Eph family receptors Sara Charmsaz, Andrew M. Scott,

Pattern Recognition Receptors

Figure 1 from M Holderfield

Molecular features of the colon during homeostasis and carcinogenesis

Figure 1 from T Schenk et al.

Mechanism of CTLA-4-induced immunosuppression.

Nat. Rev. Endocrinol. doi: /nrendo

Fbxw7 ablation in LICs for CML sensitises the cells to imatinib by preventing quiescence. Figure 2 from S Takeishi British Journal of Cancer (2014) 111,

HDACs class I, II, IV mutations in human cancer

In melanoma tumours expressing the BRAFV600E oncogene RAF inhibitor treatment decreases ERK activation resulting in tumour regression and increased survival.

Figure 1 Mechanisms of action of immunotherapy modalities

Mitochondrial priming model

Spectrum of cellular processes regulated by AXL activity

Figure 1 from D’Incalci et al.

Involvement of actin cytoskeletal reorganisation in EMT

The F-box protein Fbxw7 is required for maintenance of normal stem cells. Figure 1 from S Takeishi British Journal of Cancer (2014) 111, ; doi: /bjc

Mechanism of PD-1/PD-L1 pathway-induced immunosuppression within the tumour microenvironment. Mechanism of PD-1/PD-L1 pathway-induced immunosuppression.

Target antigens for ADCs in solid tumours

Macrophage differentiation and their role in tumourigenesis

Model of EphA/ephrin-A expression in GBM.

Distribution of immune checkpoint in tumor cells and immune microenvironment. CTLA-4, cytotoxic T lymphocyte antigen-4; MHC, major histocompatibility complex;

Releasing the Brakes on Cancer Immunotherapy

(A) Lymph node priming phase: recognition of major histocompatibility complex (MHC) by T-cell receptor (TCR), coactivating CD 28/B7 pathway activation.

Human cancer immunotherapy strategies targeting B7-H3 A, blockade of B7-H3 with blocking mAbs neutralizes inhibitory signaling in its unidentified receptor(s)

Presentation transcript:

The cellular immune response to cancer is complex and involves a diverse repertoire of immunoregulatory interactions principally involving antigen presenting cells (APC), T cells, and tumour cells Figure 1 from Cogdill et al. British Journal of Cancer Advance Online Publication 18 May 2017 doi:10.1038/bjc.2017.136 Several approaches exist to target Eph receptors. Kinase inactivating strategies include kinase inhibitors or blocking peptides or antibodies. Kinase activating strategies include ligand stimulation, activating antibodies or ligand peptide mimetics Strategies to deliver toxic payloads following receptor activation and internalisation include coupling of cytotoxic agents or radionuclides to Eph monoclonal antibodies. © 2017 The Author(s).